% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{EstradaCuzcano:139142,
author = {Estrada-Cuzcano, Alejandro and Martin, Shaun and Chamova,
Teodora and Synofzik, Matthis and Timmann, Dagmar and
Holemans, Tine and Andreeva, Albena and Reichbauer, Jennifer
and De Rycke, Riet and Chang, Dae-In and van Veen, Sarah and
Samuel, Jean and Schöls, Ludger and Pöppel, Thorsten and
Mollerup Sørensen, Danny and Asselbergh, Bob and Klein,
Christine and Zuchner, Stephan and Jordanova, Albena and
Vangheluwe, Peter and Tournev, Ivailo and Schüle, Rebecca},
title = {{L}oss-of-function mutations in the {ATP}13{A}2/{PARK}9
gene cause complicated hereditary spastic paraplegia
({SPG}78).},
journal = {Brain},
volume = {140},
number = {2},
issn = {0006-8950},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DZNE-2020-05464},
pages = {287-305},
year = {2017},
abstract = {Hereditary spastic paraplegias are heterogeneous
neurodegenerative disorders characterized by progressive
spasticity of the lower limbs due to degeneration of the
corticospinal motor neurons. In a Bulgarian family with
three siblings affected by complicated hereditary spastic
paraplegia, we performed whole exome sequencing and
homozygosity mapping and identified a homozygous p.Thr512Ile
(c.1535C > T) mutation in ATP13A2. Molecular defects in this
gene have been causally associated with Kufor-Rakeb syndrome
(#606693), an autosomal recessive form of juvenile-onset
parkinsonism, and neuronal ceroid lipofuscinosis (#606693),
a neurodegenerative disorder characterized by the
intracellular accumulation of autofluorescent lipopigments.
Further analysis of 795 index cases with hereditary spastic
paraplegia and related disorders revealed two additional
families carrying truncating biallelic mutations in ATP13A2.
ATP13A2 is a lysosomal P5-type transport ATPase, the
activity of which critically depends on catalytic
autophosphorylation. Our biochemical and immunocytochemical
experiments in COS-1 and HeLa cells and patient-derived
fibroblasts demonstrated that the hereditary spastic
paraplegia-associated mutations, similarly to the ones
causing Kufor-Rakeb syndrome and neuronal ceroid
lipofuscinosis, cause loss of ATP13A2 function due to
transcript or protein instability and abnormal intracellular
localization of the mutant proteins, ultimately impairing
the lysosomal and mitochondrial function. Moreover, we
provide the first biochemical evidence that disease-causing
mutations can affect the catalytic autophosphorylation
activity of ATP13A2. Our study adds complicated hereditary
spastic paraplegia (SPG78) to the clinical continuum of
ATP13A2-associated neurological disorders, which are
commonly hallmarked by lysosomal and mitochondrial
dysfunction. The disease presentation in our patients with
hereditary spastic paraplegia was dominated by an
adult-onset lower-limb predominant spastic paraparesis.
Cognitive impairment was present in most of the cases and
ranged from very mild deficits to advanced dementia with
fronto-temporal characteristics. Nerve conduction studies
revealed involvement of the peripheral motor and sensory
nerves. Only one of five patients with hereditary spastic
paraplegia showed clinical indication of extrapyramidal
involvement in the form of subtle bradykinesia and slight
resting tremor. Neuroimaging cranial investigations revealed
pronounced vermian and hemispheric cerebellar atrophy.
Notably, reduced striatal dopamine was apparent in the brain
of one of the patients, who had no clinical signs or
symptoms of extrapyramidal involvement.},
keywords = {Adult / Animals / Cells, Cultured: cytology / Cells,
Cultured: ultrastructure / Chlorocebus aethiops / Cognition
Disorders: etiology / Cognition Disorders: genetics / Enzyme
Inhibitors: pharmacology / Family Health / Gene Expression
Regulation: drug effects / Gene Expression Regulation:
genetics / Genetic Predisposition to Disease: genetics /
Humans / Leupeptins: pharmacology / Lysosomes: drug effects
/ Lysosomes: metabolism / Lysosomes: ultrastructure / Male /
Mental Disorders: etiology / Mental Disorders: genetics /
Middle Aged / Mitochondria: drug effects / Mitochondria:
metabolism / Mitochondria: ultrastructure / Mutation:
genetics / Neuropsychological Tests / Proton-Translocating
ATPases: genetics / Psychiatric Status Rating Scales /
Spastic Paraplegia, Hereditary: complications / Spastic
Paraplegia, Hereditary: diagnostic imaging / Spastic
Paraplegia, Hereditary: genetics / ATP13A2 protein, human
(NLM Chemicals) / Enzyme Inhibitors (NLM Chemicals) /
Leupeptins (NLM Chemicals) / Proton-Translocating ATPases
(NLM Chemicals) / benzyloxycarbonylleucyl-leucyl-leucine
aldehyde (NLM Chemicals)},
cin = {AG Gasser 1 / AG Schöls 1 / AG Maetzler},
ddc = {610},
cid = {I:(DE-2719)1210000 / I:(DE-2719)5000005 /
I:(DE-2719)5000024},
pnm = {345 - Population Studies and Genetics (POF3-345) / 344 -
Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-345 / G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28137957},
pmc = {pmc:PMC5278306},
doi = {10.1093/brain/aww307},
url = {https://pub.dzne.de/record/139142},
}